Cerus Corporation (NASDAQ:CERS) — Market Cap & Net Worth
Market Cap & Net Worth: Cerus Corporation (CERS)
Cerus Corporation (NASDAQ:CERS) has a market capitalization of $522.96 Million ($522.96 Million) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #12093 globally and #3037 in its home market, demonstrating a 5.98% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Cerus Corporation's stock price $2.66 by its total outstanding shares 200368974 (200.37 Million). Also see Cerus Corporation asset portfolio for a full breakdown of the balance sheet.
Cerus Corporation Market Cap History: 2015 to 2026
Cerus Corporation's market capitalization history from 2015 to 2026. Data shows change from $1.27 Billion to $532.98 Million (-4.85% CAGR). Also see cash efficiency ratio of Cerus Corporation for how efficiently the company converts equity into cash flow.
Index Memberships
Cerus Corporation is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.67 Trillion | 0.02% | #333 of 976 |
|
NASDAQ Composite
IXIC
|
$41.95 Trillion | 0.00% | #1203 of 3165 |
Weight: Cerus Corporation's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Cerus Corporation Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Cerus Corporation's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check latest Cerus Corporation stock price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
2.00x
Cerus Corporation's market cap is 2.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $871.61 Million | $37.18 Million | -$62.91 Million | 23.44x | N/A |
| 2017 | $677.25 Million | $43.57 Million | -$60.59 Million | 15.54x | N/A |
| 2018 | $1.02 Billion | $60.91 Million | -$57.56 Million | 16.68x | N/A |
| 2019 | $845.56 Million | $74.65 Million | -$71.24 Million | 11.33x | N/A |
| 2020 | $1.39 Billion | $91.92 Million | -$59.86 Million | 15.08x | N/A |
| 2021 | $1.36 Billion | $130.86 Million | -$54.38 Million | 10.43x | N/A |
| 2022 | $731.35 Million | $162.05 Million | -$42.83 Million | 4.51x | N/A |
| 2023 | $432.80 Million | $156.37 Million | -$37.49 Million | 2.77x | N/A |
| 2024 | $308.57 Million | $180.27 Million | -$20.92 Million | 1.71x | N/A |
| 2025 | $412.76 Million | $206.13 Million | -$15.63 Million | 2.00x | N/A |
Competitor Companies of CERS by Market Capitalization
Companies near Cerus Corporation in the global market cap rankings as of September 18, 2026. Review CERS goodwill-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Cerus Corporation by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #126 globally with a market cap of $177.76 Billion USD.
- Medtronic PLC (NYSE:MDT): Ranked #229 globally with a market cap of $109.30 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #235 globally with a market cap of $107.45 Billion USD.
- Medtronic plc (SA:MDTC34): Ranked #241 globally with a market cap of $104.84 Billion USD ( R$534.32 Billion BRL).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #126 | Abbott Laboratories | NYSE:ABT | $177.76 Billion | $102.23 |
| #229 | Medtronic PLC | NYSE:MDT | $109.30 Billion | $92.77 |
| #235 | Stryker Corporation | NYSE:SYK | $107.45 Billion | $280.13 |
| #241 | Medtronic plc | SA:MDTC34 | $104.84 Billion | R$208.39 |
Cerus Corporation Historical Marketcap From 2015 to 2026
Between 2015 and today, Cerus Corporation's market cap moved from $1.27 Billion to $ 532.98 Million, with a yearly change of -4.85%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $532.98 Million | +29.13% |
| 2025 | $412.76 Million | +33.77% |
| 2024 | $308.57 Million | -28.70% |
| 2023 | $432.80 Million | -40.82% |
| 2022 | $731.35 Million | -46.40% |
| 2021 | $1.36 Billion | -1.59% |
| 2020 | $1.39 Billion | +63.98% |
| 2019 | $845.56 Million | -16.77% |
| 2018 | $1.02 Billion | +50.00% |
| 2017 | $677.25 Million | -22.30% |
| 2016 | $871.61 Million | -31.17% |
| 2015 | $1.27 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 18th, 2026 the market cap of Cerus Corporation was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $522.96 Million USD |
| MoneyControl | $522.96 Million USD |
| MarketWatch | $522.96 Million USD |
| marketcap.company | $522.96 Million USD |
| Reuters | $522.96 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Cerus Corporation
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The company offers INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company also offer… Read more